The local therapy of breast cancer is based on a strong foundation of evidence derived from prospective randomized trials comparing local recurrence and survival outcomes after breast-conserving therapy (BCT) to those after mastectomy (1). Although there is no survival advantage to mastectomy, approximately 25% of women with ductal carcinoma in situ and stage I and II breast cancer undergo mastectomy due to patient preference or contraindications to BCT (2,3), and the use of contralateral prophylactic mastectomy appears to be increasing (4). Together, these factors mean that a substantial proportion of women undergoing surgical treatment for
The local therapy of breast cancer is based on a strong foundation of evidence derived from prospective randomized trials comparing local recurrence and survival outcomes after breast-conserving therapy (BCT) to those after mastectomy (1) . Although there is no survival advantage to mastectomy, approximately 25% of women with ductal carcinoma in situ and stage I and II breast cancer undergo mastectomy due to patient preference or contraindications to BCT (2, 3) , and the use of contralateral prophylactic mastectomy appears to be increasing (4) . Together, these factors mean that a substantial proportion of women undergoing surgical treatment for breast cancer are candidates for unilateral or bilateral breast reconstruction. Survey research suggests that patient knowledge of reconstructive options statistically increases willingness to consider mastectomy (5) . In a study of women from the Los Angeles and Detroit Surveillance, Epidemiology, and End Results registries diagnosed with breast cancer between 2001 and 2003, Alderman et al. (5) found that those who discussed reconstruction with their general surgeon were four times more likely to undergo mastectomy than those who did not (odds ratio, 4.48; 95% confidence interval, 3.31 to 6.06; P < .001) after controlling for age, race, education, and comorbidities (5) . The discussion about breast reconstruction includes a description of the spectrum of reconstructive options, the incidence and types of complications, and the long-term cosmetic results. Unfortunately, as documented by Potter et al. in this issue of the Journal (6), reliable information on these outcomes is difficult to obtain. Of the 134 studies evaluating surgical complications after reconstruction, only 11 (8.2%) were prospective randomized trials, 49 (36.6%) were case series, and the remainder cohort studies. Important discrepancies between the number of outcomes defined and the number reported were observed for the majority of studies, and key information such as the method of complication assessment, duration of follow-up, and distribution of risk factors among the patients studied was missing in many instances. This variability in reporting makes both an assessment of the generalizability of the findings of individual studies and comparison among studies difficult. There is clearly an opportunity to improve the quality of information that is available to patients faced with a breast cancer surgery decision that includes reconstruction, and the development of a rigorously defined set of core outcome measures is a logical first step.
The recent UK National Mastectomy and Breast Reconstruction Audit was an important step toward the goal of standardized reporting of outcomes (7). The audit prospectively evaluated in-hospital complications and patient-reported outcomes in a large cohort of patients treated at over 200 surgical centers. Before the initiative, standardized definitions of complication were developed. This report thus provides high-quality information on the incidence of adverse events that may directly inform and support shared medical decision making for patients and surgeons. As an example, the audit identified that one in six women undergoing reconstruction required re-admission for unplanned further treatment or surgery and that one in four required antibiotics for a wound infection. The audit also provided concrete benchmark data that will be useful for quality improvement efforts, and it would be advisable for researchers and surgical societies elsewhere in the world to strongly consider adoption of similar definitions for standardized reporting.
Evidence suggests that patients may more sensitively discern and reliably report adverse events than their physicians (8) . As an example, among patients undergoing sentinel node biopsy or axillary dissection, there is striking discordance between the presence of measured and patient-perceived lymphedema (9) , suggesting that consideration be given to standardization of patient, as well as clinician-reported outcomes (10) . High-quality standardized information on patient satisfaction with various aspects of reconstruction is also needed. Patient perceptions may differ in important ways from those of their physicians (10). For example, physician assumptions that a contralateral prophylactic mastectomy for symmetry, with the resultant anesthetic breast, is preferable to a mastopexy or reduction, which provides less-perfect symmetry but maintains a sensate breast, may not reflect patient values. Three systematic reviews have confirmed that research evaluating patientreported outcomes in breast reconstruction has been limited by the absence of a standardized condition-specific measure (11) (12) (13) . Studies have relied on generic measures (such as the SF-36 health survey questionnaire) or "nonsurgical" breast cancer-specific measures (such as the European Organization for the Research and Treatment quality-of-life questionnaire [EORTC-BR23] or Functional Assessment of Cancer Therapy-Breast [FACT-B]), which have proven to be relatively insensitive to the unique issues of breast reconstruction patients (eg, body image and sexual well-being).
The BREAST-Q, a new patient-reported outcome measure with a condition-specific "reconstruction module," was developed to address this need (14) . It has been translated into and linguistically validated in 11 languages, and is being used extensively worldwide. As a condition-specific measure, the BREAST-Q may be able to detect more subtle differences in reconstructive outcomes. Research using the BREAST-Q has confirmed statistically significant differences in long-term patient satisfaction comparing TRAM (transverse rectus abdominus myocutaneous flap) to implant breast reconstruction (15) . In other studies among patients undergoing implant reconstruction, higher satisfaction has been noted among recipients of silicone compared with saline implants (16, 17) . Such standardized assessment may inform not only technical innovation, but also patient education and decision making. In the UK National Audit, the BREAST-Q was used to examine patient satisfaction with preoperative information; approximately one-half of women were not fully satisfied with the information they received on what their scars would look like and what postoperative pain to expect. The audit identified knowing "what other women experience with their surgery" as the area for which the lowest level of full satisfaction was reported, suggesting an important area for improvement in patient education.
As we seek to better inform our patients and address their needs, a new era of both clinician-and patient-reported outcomes is needed. For many years, the continued use of mastectomy in the United States was attributed to the failure of surgeons to involve patients in the decision-making process and the belief that surgeons favored mastectomy over BCT. Population-based studies (2,3) have shown that patient preference is a major determinant of mastectomy rates, and a high degree of patient involvement in surgical decision making is associated with a statistically significant increase in mastectomy rates compared with those seen when the surgeon is the primary decision maker. In a recent study of 449 young breast cancer survivors, the proportion expressing regret over their reconstructive procedure (17.8%) differed little from the proportion expressing regret over primary surgery (24.1%), and chemotherapy and radiotherapy decisions (21.5%). The unifying theme across these treatment areas was dissatisfaction with the information provided regarding treatment alternatives and side effects (18) . An emerging body of data, including the work of Potter et al. (6) reported here, indicates that current standards of outcome reporting are of limited benefit to both patients and physicians. In contrast to the search for new breast cancer therapies to improve survival, a long-term and enormously expensive task, improved standards for outcome reporting for reconstruction, and other aspects of breast cancer treatment have the potential to improve patient quality of life in the short term at relatively modest cost.
